Decode the Undetected Your Gateway to ECHO Insights

Decode the Undetected

Your Gateway to ECHO Insights

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive, and infiltrative form of Cardiomyopathy that can often be overlooked as a cause of Heart Failure ^1,2. Rapid advances in non-invasive cardiac imaging and disease awareness have shifted ATTR-CM from a difficult to diagnose disease to a disease that can be suspected early, based on red flags ³.

Login to decipher

the echocardiography red flags to raise suspicion and facilitate an early diagnosis of cardiac amyloidosis.

First Name:

Last Name:

Email:

I am the Registered Medical Practitioner authorized to practice in India

By submitting this information, I provide my consent to Pfizer Medical Team to contact me relating to information of Echocardiography Practical Points and ATTR-CM.

Disclaimer:

This message is intended for Registered Medical Practitioners authorized to practice in India.

This content is intended for your personal and educational use only. Please do not share or distribute this material. Reproduction or distribution of this content, in whole or in part, is not permitted without the permission of the copyright owner(s).

All information published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the package insert.

While due care and caution has been taken to ensure that the content here is free from mistakes or omissions, Pfizer makes no claims, promises, or guarantees about the accuracy, completeness, or adequacy of the information here.

The views expressed by any author herein are their own independent views and Pfizer may not necessarily endorse the same.

The echocardiographic images are provided by the author.

You may report an adverse event related to Pfizer products by emailing us at IND.AEReporting@pfizer.com or via Fax at: 000800100-5961 / +91-22 3919-771

References:

1. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019 Aug;7(8):709-716.

2. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72.

3. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023 Feb 3;118(18):3517-3535.

For the use only of registered medical practitioners or a hospital or a laboratory